CClinicalTrials.gg
Status unknownNCT03179371pro-CDHUpdated Jul 18, 2018

Proteomic Profiling for Congenital Diaphragmatic Hernia

An observational study in Congenital Diaphragmatic Hernia, sponsored by Centre Hospitalier Universitaire de Besancon. Status unknown at 2 sites in France. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2018-07-18.

Sponsored by Centre Hospitalier Universitaire de Besancon · Observational

The sponsor has not verified this record recently (last verified Jul 2018), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
10
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

Congenital diaphragmatic hernia (CDH) is a severe congenital malformation, related to a developmental defect of the diaphragm. The incidence of CDH is approximated at 1 in 3,000 live births. Although advances in surgery and neonatal intensive care have improved the prognosis, mortality remains high, around 30-50% related to severe lung hypoplasia and persistent pulmonary hypertension. Prenatal evaluation with observed/expected Lung over Head Ratio (o/e LHR), liver position and total lung volume measured by magnetic resonance, have been shown to correlate with neonatal mortality . However, the preponderant factor of persistent pulmonary hypertension remains difficult to predict prenatally. In patients with isolated diaphragmatic hernia (without associated malformations or karyotype abnormalities), prognosis is evaluated indirectly on pulmonary development from pulmonary volume measurements. Apart from the most caricatural cases with extremely good or very pejorative values, for a large proportion of fetuses with diaphragmatic dome hernia the prognosis remains uncertain.

The aim of the proposal is to investigate whether the analysis of the proteom of the amniotic fluid of the fetuses with CDH could give information of a prognostic character. The objective of the study is to identify, from the proteomic profile of the amniotic fluid of mothers whose fetus has CDH, prognostic markers candidates for death at 2 months of the infant. The first step is to carry out an exploratory and non-interventional study on a small sample (n = 10) of the target population. This is a preliminary step before considering, if the results are encouraging, a large-scale study from a biological collection to determine candidate proteins (new biomarkers) which relative expression levels could be used as surrogate marker of pulmonary hypoplasia.

Read the detailed description

Pregnant patients for whom amniocentesis will be performed as part of the prenatal management of CDH confirmed by fetal ultrasound will be approached fot inclusion in the study. The indication of amniocentesis will be indicated according to the usual standards of care. Briefly, the study will not involve any additional invasive procedure. In our study, amniocentesis will be indicated during the conventional management of these patients. The needs of our research will not lead to additional amniocenteses, but simply an increase in the volume of amniotic fluid collected. An additional volume of 5 ml will be sampled for volumes usually taken from 20 to 30 ml. This volume of sampling will have a very limited impact on maternal and fetal well-being. An analysis of the proteom of the amniotic fluid of the patients will be carried out. The relative amounts of proteins and peptides contained in the amniotic fluid will be analyzed to explore variations in proteomic profile that may reflect different clinical gravity in terms of further evolution. The usual management of the patients and their children will not be modified by the procedures related to the research.

The first step will consist in carrying out a depletion of the major proteins, in particular albumin. A protein assay will be carried out from the same amount of protein for each sample (standardization). This depletion step will be followed by a migration step on a gel of 1D electrophoresis. Its purpose is both to eliminate all the contaminants that can hinder mass spectrometry analysis, to separate the proteins according to their molecular weight in order to simplify the protein mixture and to have a visual control of the heterogeneity of the sample. A differential visual analysis after staining will allow to define the highly variable zones between the groups of patients and within the same sample. We will select the zone of interest in identical manner for each sample and for the whole of the gel track. The use of commercial electrophoresis gels of the same batch and the parallel analysis of several samples of different groups and the use of quality controls ensure reproducibility. The proteins contained in these bands / gel zones are then digested according to a standardized protocol under controlled conditions. The simultaneous treatment of the different biological samples makes it possible to considerably reduce the impact of the variability of this step in the final differential statistical analysis. At the end of this step the proteins are analyzed by an LC-ESI MS / MS approach. This LC-ESI MS / MS approach consists of separating the peptides on a chromatographic separation column which is coupled directly to the ESI-MS / M mass spectrometer. This analytical approach can allow the identification of more than 1000 proteins and 5000 peptides. This analysis is repeated 3 times per sample so that analytical variability can be taken into account in differential statistical studies. At the end of this protocol the raw data of each zone are pooled by sample and the differential statistical study can be carried out.

02

Conditions studied

03

In context

Hernias, Diaphragmatic, Congenital

93 studies on the registry are indexed under Hernias, Diaphragmatic, Congenital; 39 are open to participants now.

This study's planned enrollment of 10 is below the median of 78 across 25 observational studies indexed under Hernias, Diaphragmatic, Congenital.

Browse Hernias, Diaphragmatic, Congenital studies →

Lead sponsor

Centre Hospitalier Universitaire de Besancon is the lead sponsor of 439 studies on the registry; 97 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Mothers whose fetus has CDH

Inclusion criteria

Pregnant patients for whom amniocentesis will be performed as part of the prenatal diagnosis of a diaphragmatic hernia.

Exclusion criteria

Exclusion Criteria:

  • Refusal of patients,
  • Refusal of spouse regarding data of the future child,
  • Multiple malformations,
  • Twin pregnancy,
  • Prenatal diagnosis of an unconfirmed diaphragmatic hernia,
  • Miscarriage after amniocentesis.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No

Groups and cohorts

  • 1

    Mothers whose fetus has CDH

06

What researchers measure

Primary outcomes

  1. Neonatal death

    Time frame: 2 months of age

Secondary outcomes

  1. Prenatal death of the fetus

    Death during pregnancy

    Time frame: 9 months

  2. Neonatal death

    Time frame: 15 days

  3. Apgar score

    Time frame: 5 min after birth

  4. Age at surgery

    Time frame: 6 months of age

  5. Need for a diaphragmatic prosthesis

    Time frame: 6 months of age

  6. Duration of ventilation (in days)

    Time frame: 6 months of age

  7. Duration of the oxygen dependency (in days)

    Time frame: 6 months of age

  8. Need of supplemental oxygen therapy

    Binary outcome (Yes/No)

    Time frame: 28 days of age

  9. Occurrence of pulmonary hypertension

    Time frame: 6 months of age

  10. Duration of parenteral nutrition (in days)

    Time frame: 6 months of age

  11. Age at the beginning of enteral nutrition

    Time frame: 6 months of age

  12. Age at the beginning of oral nutrition

    Time frame: 6 months of age

  13. Duration of hospital stay (in days)

    Time frame: 6 months of age

07

Study locations

1 of 2 sites recruiting
  • CHU de Besançon
    Besançon, 25000, France
    Active, not recruiting
  • CHU de Dijon
    Dijon, 21000, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 18, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03179371
Lead sponsor
Centre Hospitalier Universitaire de Besancon
Collaborators
FEMTO-ST
Responsible party
Sponsor
First posted
Jun 7, 2017
Start date
May 18, 2017
Primary completion
Jul 2019 (estimated)
Completion
Nov 2019 (estimated)
Last update
Jul 18, 2018

Study contacts

Frédéric Auber, Professor
Contact
fauber@chu-besancon.fr
+ 33 3 81 21 82 21

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion